Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference

2010 ◽  
Vol 46 (12) ◽  
pp. 2166-2177 ◽  
Author(s):  
Daniel S.-W. Tan ◽  
Marco Gerlinger ◽  
Bin-Tean Teh ◽  
Charles Swanton
Keyword(s):  
Drug Resistance ◽  
Rna Interference ◽  
Cancer Drug ◽  
Integrative Genomics ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Functional Rna

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

2020 ◽  
Vol 48 ◽  
pp. 100663 ◽  
Author(s):  
Silpa Narayanan ◽  
Chao-Yun Cai ◽  
Yehuda G. Assaraf ◽  
Hui-Qin Guo ◽  
Qingbin Cui ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Ubiquitin Proteasome Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway

scholarly journals A Compendium of Information on the Lysosome

2021 ◽  
Vol 9 ◽  
Author(s):  
Nadia Bouhamdani ◽  
Dominique Comeau ◽  
Sandra Turcotte
Keyword(s):  
Drug Resistance ◽  
Scientific Knowledge ◽  
Targeted Therapies ◽  
Cancer Drug ◽  
Functional Changes ◽  
The Past ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Long Time ◽  
Signaling Organelles

For a long time, lysosomes were considered as mere waste bags for cellular constituents. Thankfully, studies carried out in the past 15 years were brimming with elegant and crucial breakthroughs in lysosome research, uncovering their complex roles as nutrient sensors and characterizing them as crucial multifaceted signaling organelles. This review presents the scientific knowledge on lysosome physiology and functions, starting with their discovery and reviewing up to date ground-breaking discoveries highlighting their heterogeneous functions as well as pending questions that remain to be answered. We also review the roles of lysosomes in anti-cancer drug resistance and how they undergo a series of molecular and functional changes during malignant transformation which lead to tumor aggression, angiogenesis, and metastases. Finally, we discuss the strategy of targeting lysosomes in cancer which could lead to the development of new and effective targeted therapies.

scholarly journals A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs

Biology ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 47 ◽  
Author(s):  
Takanori Eguchi ◽  
Eman Ahmed Taha ◽  
Stuart K. Calderwood ◽  
Kisho Ono
Keyword(s):  
Drug Resistance ◽  
Tumor Cells ◽  
Epithelial Mesenchymal Transition ◽  
Cancer Drug ◽  
Cell Phenotype ◽  
Mesenchymal Transition ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Secretory Phenotype ◽  
Novel Model

Extracellular vesicles (EVs), such as exosomes or oncosomes, often carry oncogenic molecules derived from tumor cells. In addition, accumulating evidence indicates that tumor cells can eject anti-cancer drugs such as chemotherapeutics and targeted drugs within EVs, a novel mechanism of drug resistance. The EV-releasing drug resistance phenotype is often coupled with cellular dedifferentiation and transformation in cells undergoing epithelial-mesenchymal transition (EMT), and the adoption of a cancer stem cell phenotype. The release of EVs is also involved in immunosuppression. Herein, we address different aspects by which EVs modulate the tumor microenvironment to become resistant to anticancer and antibody-based drugs, as well as the concept of the resistance-associated secretory phenotype (RASP).

Sign in / Sign up

Export Citation Format

Share Document